Daniel C Danila
Overview
Explore the profile of Daniel C Danila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ridouani F, Vargas H, Holzwanger D, Schoder H, Waters E, Petre E, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39095299
Background And Objective: The source of tissue for genomic profiling of metastatic castration-resistant prostate cancer (mCRPC) is often limited to osseous metastases. To guide patient management, metastatic site selection and...
2.
de Almeida D, Anderson J, Danila D, Morris M, Slovin S, Abida W, et al.
J Immunother Precis Oncol
. 2023 Dec;
6(4):162-169.
PMID: 38143953
Introduction: Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of life, and longer...
3.
Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, et al.
Cancer Discov
. 2023 Oct;
14(1):76-89.
PMID: 37861461
Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential...
4.
Gironda D, Bergan R, Alpaugh R, Danila D, Chuang T, Hurtado B, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509385
Despite advancements in the early-stage detection and expansion of treatments for prostate cancer (PCa), patient mortality rates remain high in patients with aggressive disease and the overtreatment of indolent disease...
5.
Smith M, Sandhu S, George D, Chi K, Saad F, Thiery-Vuillemin A, et al.
J Manag Care Spec Pharm
. 2023 Jul;
29(7):758-768.
PMID: 37404070
Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2...
6.
Breen K, Symecko H, Spielman K, Gebert R, Shah I, Pundock S, et al.
J Urol
. 2023 Mar;
209(5):918-927.
PMID: 36974724
Purpose: Genetic testing may alter clinical management for individuals with metastatic prostate cancer by identifying additional therapies. Traditional counseling models are unlikely to enable time-sensitive therapeutic decision-making. This study aimed...
7.
Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1929-1937.
PMID: 36897758
Purpose: In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizing PSMA expression could be useful in...
8.
Truong H, Breen K, Nandakumar S, Sjoberg D, Kemel Y, Mehta N, et al.
Eur Urol
. 2022 Sep;
83(1):29-38.
PMID: 36115772
Background: Tumor-only genomic profiling is an important tool in therapeutic management of men with prostate cancer. Since clinically actionable germline variants may be reflected in tumor profiling, it is critical...
9.
Keegan N, Vasselman S, Barnett E, Nweji B, Carbone E, Blum A, et al.
Prostate
. 2022 May;
82(11):1107-1116.
PMID: 35538298
Background: Routine clinical data from clinical charts are indispensable for retrospective and prospective observational studies and clinical trials. Their reproducibility is often not assessed. We developed a prostate cancer-specific database...
10.
Anand A, Heller G, Fox J, Danila D, Bjartell A, Edenbrandt L, et al.
Clin Genitourin Cancer
. 2022 Mar;
20(3):270-277.
PMID: 35279418
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) criteria is a radiographic endpoint. The automated bone scan index (aBSI) quantifies osseous disease burden on bone scintigraphy as...